Hemogenyx Pharmaceuticals PLC Announces First-in-Human Treatment with HG-CT-1
Hemogenyx Pharmaceuticals (LSE:HEMO) has announced a significant milestone with the first-in-human administration of HG-CT-1, their proprietary CAR-T cell therapy, for treating relapsed or refractory acute myeloid leukemia (R/R AML) in adults. This development represents a important step in the company's clinical development program, aiming to provide a potential life-saving treatment for AML patients with therapeutic options.
The company, headquartered in London with US operations in New York City, is a clinical-stage biopharmaceutical group focused on developing new treatments for blood and autoimmune diseases. Their mission includes expanding access to bone marrow transplantation's curative potential for patients with otherwise incurable life-threatening diseases.
Hemogenyx Pharmaceuticals (LSE:HEMO) ha annunciato un traguardo significativo con la prima somministrazione nell'uomo di HG-CT-1, la loro terapia CAR-T proprietaria, per il trattamento della leucemia mieloide acuta relapsa o refrattaria (R/R AML) negli adulti. Questo sviluppo rappresenta un passo importante nel programma di sviluppo clinico dell'azienda, con l'obiettivo di fornire un trattamento potenzialmente salvavita per i pazienti con AML che hanno opzioni terapeutiche limitate.
L'azienda, con sede a Londra e operazioni negli Stati Uniti a New York City, è un gruppo biofarmaceutico in fase clinica focalizzato sullo sviluppo di nuovi trattamenti per malattie ematiche e autoimmuni. La loro missione include l'espansione dell'accesso al potenziale curativo del trapianto di midollo osseo per i pazienti affetti da malattie altrimenti incurabili e potenzialmente letali.
Hemogenyx Pharmaceuticals (LSE:HEMO) ha anunciado un hito significativo con la primera administración en humanos de HG-CT-1, su terapia CAR-T propietaria, para el tratamiento de la leucemia mieloide aguda en recaída o refractaria (R/R AML) en adultos. Este desarrollo representa un paso importante en el programa de desarrollo clínico de la compañía, con el objetivo de proporcionar un tratamiento potencialmente salvavidas para los pacientes con AML que tienen opciones terapéuticas limitadas.
La empresa, con sede en Londres y operaciones en Estados Unidos en Nueva York, es un grupo biofarmacéutico en etapa clínica enfocado en desarrollar nuevos tratamientos para enfermedades hematológicas y autoinmunes. Su misión incluye ampliar el acceso al potencial curativo del trasplante de médula ósea para pacientes con enfermedades potencialmente mortales que de otro modo serían incurables.
Hemogenyx Pharmaceuticals (LSE:HEMO)는 성인에서 재발성 또는 불응성 급성 골수성 백혈병(R/R AML) 치료를 위한 그들의 독자적인 CAR-T 세포 치료제인 HG-CT-1의 첫 번째 인체 투여와 관련하여 중요한 이정표를 발표했습니다. 이 발전은 치료 옵션이 제한된 AML 환자에게 잠재적인 생명 구제 치료를 제공하는 것을 목표로 하는 회사의 임상 개발 프로그램에서 중요한 단계로 여겨집니다.
회사는 런던에 본사를 두고 있으며 뉴욕시에 미국 사업을 운영하는 임상 단계의 생명공학 그룹으로, 혈액 및 자가면역 질환을 위한 새로운 치료법 개발에 집중하고 있습니다. 그들의 사명은 다른 방법으로는 치유할 수 없는 생명을 위협하는 질병을 가진 환자들을 위해 골수 이식의 치유 잠재력에 대한 접근을 넓히는 것을 포함합니다.
Hemogenyx Pharmaceuticals (LSE:HEMO) a annoncé une étape importante avec la première administration chez l'homme de HG-CT-1, leur thérapie CAR-T propriétaire, pour traiter la leucémie myéloïde aiguë récurrente ou réfractaire (R/R AML) chez les adultes. Ce développement représente une étape importante dans le programme de développement clinique de l'entreprise, visant à fournir un traitement potentiellement salvateur pour les patients atteints de LMA avec des options thérapeutiques limitées.
L'entreprise, dont le siège est à Londres et qui possède des opérations aux États-Unis à New York, est un groupe biopharmaceutique en phase clinique axé sur le développement de nouveaux traitements pour les maladies sanguines et auto-immunes. Leur mission inclut l'expansion de l'accès au potentiel curatif de la transplantation de moelle osseuse pour les patients atteints de maladies potentiellement mortelles autrement incurables.
Hemogenyx Pharmaceuticals (LSE:HEMO) hat einen bedeutenden Meilenstein mit der ersten Verabreichung am Menschen von HG-CT-1, ihrer proprietären CAR-T-Zelltherapie, zur Behandlung von rezidivierter oder refraktärer akuter myeloischer Leukämie (R/R AML) bei Erwachsenen bekannt gegeben. Diese Entwicklung stellt einen wichtigen Schritt im klinischen Entwicklungsprogramm des Unternehmens dar, das darauf abzielt, eine potenziell lebensrettende Behandlung für AML-Patienten mit begrenzten Therapieoptionen bereitzustellen.
Das Unternehmen mit Sitz in London und US-Standorten in New York City ist eine biopharmazeutische Gruppe in der klinischen Phase, die sich auf die Entwicklung neuer Behandlungen für Blut- und Autoimmunerkrankungen konzentriert. Ihre Mission umfasst die Erweiterung des Zugangs zum heilenden Potenzial von Knochenmarktransplantationen für Patienten mit ansonsten unheilbaren lebensbedrohlichen Krankheiten.
- Achievement of first-in-human clinical trial milestone with HG-CT-1
- Advancement in development of potential treatment for underserved R/R AML patients
- None.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK MAR) IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
First-in-Human Treatment with HG-CT-1 for Relapsed or Refractory Acute Myeloid Leukemia
LONDON, UNITED KINGDOM / ACCESS Newswire / February 24, 2025 / Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company")(LSE:HEMO) is pleased to announce the administration of its first-in-human dose of HG-CT-1, its proprietary CAR-T cell therapy, for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML) in adults. This marks a major milestone in the Company's clinical development program, demonstrating progress toward delivering a potentially life-saving treatment for AML patients with limited therapeutic options.
Further updates on the clinical trial will be provided in due course.
Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented:
"We are thrilled to take this critical step in advancing the development of HG-CT-1. This milestone not only validates our years of research and development, but also brings us closer to providing a transformative treatment for patients suffering from relapsed or refractory AML."
Enquiries:
Hemogenyx Pharmaceuticals plc | |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | |
Peter Redmond, Director | |
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Adam Cowl | |
Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow | |
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.
The Company is a clinical-stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View the original press release on ACCESS Newswire
FAQ
What is the significance of Hemogenyx's HG-CT-1 first-in-human treatment for HOPHF investors?
What medical condition does Hemogenyx's HG-CT-1 therapy target?
What type of therapy is HG-CT-1?
When did Hemogenyx announce its first human treatment with HG-CT-1?
